Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Kyverna Therapeutics Inc (KYTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.61-10.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for KYTX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash runway into 2028 | Kyverna Therapeutics aims to maintain a cash runway into 2028. | Intact | Cash runway falls short of 2028 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Financial Results for the Second Quarter Ended June 30, 2026 • Kyverna reported $199.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which in addition to amounts available for draw from the Oxford Finance amended loan facility, is expected to provide operating runway into 2028.” “• Research and Development (R&D) expenses were $24.8 million for the second quarter ended June 30, 2026.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making biotechnology company rather than an established compounder. The thesis is on watch: management reports progress toward the miv-cel submission and launch, but recent financial performance is below its industry cohort and confidence in the evidence is low.
The snapshot provides no valuation measure or direct evidence about market expectations, so whether KYTX looks cheap, fair, or expensive versus peers is unclear. The available evidence points to expectations being sensitive to clinical and regulatory execution, but it does not show what the market already assumes.
Near term, management says it remains on track to complete the rolling BLA submission for miv-cel in SPS by Q4 2026, while preparing for a potential 2027 launch. Cash declined from $279.3 million at 2025-Q4 to $199.4 million at 2026-Q2; management continues to state a runway into 2028, but the decline shows ongoing cash use. A guidance cut, weaker results, or slower progress could pressure the thesis; the snapshot rates near-term miss risk as quiet but notes a 38% miss probability.
The multi-year view depends on completing the submission, securing scalable manufacturing, and making launch preparations translate into commercial readiness. The downside case includes a guidance cut or continued labor-market weakening, which could increase recession concerns for cyclical names. Continued strong results and guidance from sector peers such as VRTX, REGN, and MRNA could support sector momentum, though that would not resolve KYTX’s company-specific execution risks.
Over the next 1 to 3 years, KYTX remains an execution-dependent biotechnology thesis with progress on miv-cel offset by cash consumption, below-cohort performance, and limited evidence on valuation expectations. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
EPS trend toward less negative losses | A supporting condition in Kyverna Therapeutics Inc's published investment case. The stated target is EPS loss narrows from -2.88 in 2026 to better levels. | Broken | EPS loss worsens beyond -2.95 in 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Fund SPS BLA filing and Phase 3 gMG trial | It plans to fund its SPS BLA filing and Phase 3 gMG trial. | Intact | Failure to fund SPS BLA filing and Phase 3 gMG trial | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.94 → $-3.12 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-07-25 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-07-26 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-07-27 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-07-28 | $-2.95 | $17,596,720 | 5 / 5 |
| 2026-07-29 | $-2.95 | $17,596,720 | 5 / 5 |
| 2026-07-30 | $-2.95 | $17,596,720 | 5 / 5 |
| 2026-07-31 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-01 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-02 | $-2.95 | $17,596,720 | 5 / 5 |
| 2026-08-03 | $-2.95 | $17,596,720 | 5 / 5 |
| 2026-08-04 | $-2.95 | $17,596,720 | 5 / 5 |
| 2026-08-05 | $-2.95 | $17,596,720 | 5 / 5 |
| 2026-08-06 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-07 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-08 | $-2.95 | $17,596,720 | 5 / 5 |
| 2026-08-09 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-10 | $-2.95 | $17,596,720 | 5 / 5 |
| 2026-08-12 | $-2.95 | $17,596,720 | 5 / 5 |
| 2026-08-13 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-14 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-15 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-16 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-17 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-18 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-19 | $-2.94 | $17,539,442 | 5 / 4 |
| 2026-08-20 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-21 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-22 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-23 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-24 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-25 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-26 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-27 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-28 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-29 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-30 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-08-31 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-01 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-02 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-03 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-04 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-05 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-06 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-07 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-08 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-09 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-10 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-11 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-12 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-13 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-14 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-15 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-16 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-17 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-18 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-19 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-20 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-21 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-22 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-23 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-24 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-25 | $-3.03 | $15,162,352 | 5 / 4 |
| 2026-09-26 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-09-27 | $-3.12 | $17,196,460 | 4 / 5 |
| 2026-09-28 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-09-29 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-09-30 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-01 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-02 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-03 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-04 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-05 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-06 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-07 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-08 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-09 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-10 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-11 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-12 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-13 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-14 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-15 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-16 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-17 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-18 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-19 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-20 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-21 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-22 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-23 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-24 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-25 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-26 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-27 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-28 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-29 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-30 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-10-31 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-11-01 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-11-02 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-11-03 | $-3.12 | $17,196,460 | 5 / 5 |
| 2026-11-04 | $-3.12 | $17,196,460 | 5 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.